What is AARD stock price today?

AARD (Aardvark Therapeutics Inc) stock is trading at $5.65 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is AARD stock going up or down today?

AARD stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy AARD stock now?

The decision to buy AARD depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is AARD a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for AARD based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is AARD stock overvalued or undervalued?

Use our DCF valuation calculator to determine if AARD is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is AARD's P/E ratio?

P/E ratio data for AARD will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is AARD's market cap?

AARD (Aardvark Therapeutics Inc) has a market capitalization of $0.11 billion, making it a small-cap stock.

What is AARD's price to book ratio?

AARD trades at a price-to-book (P/B) ratio of 1.07, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does AARD pay dividends?

AARD does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is AARD's dividend yield?

AARD does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is AARD stock a good long-term investment?

AARD's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is AARD's revenue growth rate?

Revenue growth data for AARD is available on our dashboard with detailed financial statement analysis.

Profitability metrics for AARD are available on our dashboard with complete income statement analysis.

What are the risks of investing in AARD?

Key risks for AARD include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does AARD compare to its competitors?

Compare AARD to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize AARD's performance and positioning.

What is AARD's stock price target for 2026?

Our AI model provides price targets for AARD based on fundamental analysis: Bull case $7.35 (+30%), Base case $6.50 (+15%), Bear case $5.09 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about AARD?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for AARD. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is AARD's next earnings report?

AARD reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

AARD - Aardvark Therapeutics Inc

NYSE * Health Care * Biotechnology

$5.65

+$0.42 (+8.03%)

About Aardvark Therapeutics Inc

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

AARD Key Statistics

Market Cap

$114.10M

P/B Ratio

1.07

EPS

$-2.93

Employees

How AARD Compares to Peers

AARD is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
AARD(This stock)	$114.10M	N/A	0%	0.0%	-
AMGNAmgen Inc	$191.53B	24.9	0%	0.2%	vs AMGN
GILDGilead Sciences	$170.84B	20.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.22B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.35B	18.1	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.91B	20.9	-0%	0.1%	vs BIIB

Aardvark Therapeutics Inc Company Information

Headquarters: California; U.S.A
Website: aardvarktherapeutics.com
Sector: Health Care
Industry: Biotechnology

Data Updated: April 21, 2026 at 9:13 AM EDT

Ready to invest in AARD?

Commission-free trading available. Affiliate links.

AARD Lician Score

5% confidence

4.0/10

Neutral

AARD has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates AARDacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

AARD Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for AARD

Dashboard

Enter a ticker to analyze